The global pyrogen testing market is expected to show a CAGR of 10% during the forecast period (2023-2032). In the process, the pyrogen testing market can successfully scale valuation of USD 4.6 billion by the end of the review period. Pyrogen is a toxin produced by bacteria. This thermostable substance, when administered parenterally, can trigger immunogenic response causing fever in human beings. It can be present in vaccines, biotechnological products, and drugs, but as its advantage, it can also read the presence of microbes and their metabolites. The technology becomes important in detecting the presence of pyrogen in substances such as drugs and vaccines. An integral process of the drug makers, this test ensures that the mixture lacks pyrogen so that the end-product does not trigger any fever.

Increasing concern related to patient safety and stringent regulations to promote safer drugs are the main thrusters for the pyrogen testing market. This has ensured a rise in the production of innovative drugs and awareness regarding products which is pushing the pyrogen testing market boundaries wider. Increasing investment in the research & development sector and government initiatives are to guide the market ahead in the coming years.

Segmentation:

MRFR, in their report on the global pyrogen testing market, segmented the market by product, test type, application and end-user for a better understanding.

Based on the product, the pyrogen testing market can be segmented into instruments, services, kits, and reagents.

Based on the test type, the pyrogen testing market can be segmented into recombinant factor C assay (rFC), limulus amoebocyte lysate (LAL) test, monocyte activation test (MAT), and rabbit pyrogen test (RPT). LAL test’s market proliferation is quite intense and its popularity among the parenteral pharmaceuticals and medical device manufacturing companies is on the rise.

Based on the application, the pyrogen testing market can be segmented into pharmaceutical & biologics, medical devices, and other applications systems.

Based on the end-user, the pyrogen testing market includes medical device companies, pharmaceutical companies, biotechnology companies, food and beverage companies. The pharmaceutical company’s segment is gaining much prominence.

Regional Analysis:

MRFR, in their latest report on the global pyrogen testing market, included North America, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) for a region-specific analysis.

North America’s dominance in the global sphere can be attributed to the presence of the U.S. The country has the superlative infrastructure for research & development and a robust healthcare system. The presence of several pharmaceuticals and biotech companies are creating scope for the market to expand with great gusto.

Europe’s dominance is a tad tinier than that of North America. The presence of several big names such as France, Germany, the U.K., and others and their substantial spending in the R & D sector to develop better drug can emerge as one the major factors pushing the market ahead. The pyrogen testing demand is also increasing as the immunity in the aged and children are really low and any kind of secondary disease can adversely impact the healing process.

The emergence of APAC is quite riveting. As developing economies trying to revamp their healthcare sector, a rise in investment regarding infrastructural development has become significant. The regional market is quite alluring to the global players for a number of reasons such as cost-effective resources and labor.

The MEA market can contribute meagerly to the global development of pyrogen testing market. The regional market has a poor infrastructure which can be a great obstacle for the market growth during the forecast period. But a rise in hospital number can ensure better growth for the pyrogen testing market in the region.

Competitive Landscape:

The pyrogen testing market players are Thermo Fisher Scientific, Inc. (US), Ellab A/S (UK), Charles River Laboratories, Inc. (US), GenScript (US), Hyglos GmbH (UK), Merck KGaA (UK), Lonza (UK), Pyrostar (Japan), Wako Chemicals (US), Sanquin (UK), WuXi PharmaTech (Cayman), Inc (China), Associates of Cape Cod, Inc. (US), and others.

In 2018, MilliporeSigma declared that they are ready to collaborate with Solvias to create a new pyrogen testing kit. The kit would be a cell-line-based Monocyte Activation Test (MAT) kit. 

Related Report:

India Thalassemia Market

India Sickle Cell Anaemia Market

Europe Pen Needle Market

Isotype Control Antibody Market

For More Information, Please Visit @ Market Research Future